Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Quest Diagnostics
(NY:
DGX
)
163.59
-0.30 (-0.18%)
Official Closing Price
Updated: 4:10 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Quest Diagnostics
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
The Top 3 Stocks in the High-Potential ‘Cancer Testing’ Market
January 18, 2024
With the value of the cancer testing market expected to soar over the next decade, here are the three best disease testing stocks to buy now.
Via
InvestorPlace
Evolving Landscape For Alzheimer's Blood Tests Gains Momentum Amid Inaccuracy Concerns
January 12, 2024
A less invasive alternative to PET scans, these tests offer quick identification for emerging treatments. Learn more about the latest advancements in Alzheimer's detection.
Via
Benzinga
Quest Diagnostics and Ultima Collaborate to Scale Ultima’s Technology in Fast-Growing Minimal Residual Disease and Whole Genome Sequencing
January 09, 2024
From
Ultima Genomics
Via
Business Wire
Consulting Firm McKinsey Concludes Opioid Litigation Settlement With $78M Agreement
January 02, 2024
Consulting giant McKinsey & Co, on Friday, agreed to a settlement of $78 million to resolve allegations tied to the opioid epidemic, as disclosed in federal court papers filed in San Francisco.
Via
Benzinga
Expert Ratings for Quest Diagnostics
December 07, 2023
Via
Benzinga
Expert Ratings for Quest Diagnostics
November 17, 2023
Via
Benzinga
Quest Diagnostics Gains Momentum: Analyst Highlights Strong Business Trends And Growth Opportunities
December 20, 2023
Truist Securities analyst David S.
Via
Benzinga
Supreme Court Set to Decide Future of Mifepristone: Showdown Looms Over FDA's Endorsement
December 13, 2023
The U.S. Supreme Court is set to deliberate on the future of mifepristone, a crucial drug employed in over half of all abortions within the U.S.
Via
Benzinga
Exposures
Product Safety
Quest Diagnostics Inc. (NYSE: DGX) Highlighted for Surprising Price Action
December 12, 2023
Via
Investor Brand Network
Opioid Crisis and Corporate Accountability: Purdue's Settlement in the Spotlight
December 04, 2023
The U.S. Supreme Court is reviewing a contentious bankruptcy settlement involving Purdue Pharma, the maker of OxyContin, and its owners, the Sackler family.
Via
Benzinga
Topics
Bankruptcy
Exposures
Financial
Legal
Half Of S&P 500 Stocks Still Below 200-Day Average, Ignoring Covid-Like Rally: 10 Bargain Plays For Latecomer Bulls
November 21, 2023
Explore the dichotomy in the latest S&P 500 rally: Strong overall performance masks the underperformance of nearly half its stocks.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Making Connections To Care: Quest Supports Inspiring Health Equity Event Hosted by Sisters on the Vineyard
August 28, 2023
Via
ACCESSWIRE
Firing on All Cylinders Indeed
November 11, 2023
Investors are seeing some big reactions to earnings results in tech and have a few reasons to think some beaten-up names might be finding their footing.
Via
The Motley Fool
Quest Diagnostics Q3: 7.7% Topline Decline, Earnings Beat, Updated Guidance & More
October 24, 2023
Quest Diagnostics Incorporated (NYSE: DGX) posted Q3 FY23 adjusted EPS of $2.22, down 5.9% Y/Y, beating the
Via
Benzinga
Topics
Earnings
Exposures
Financial
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
October 17, 2023
EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NASDAQ:GH),(NASDAQ:NTRA),(NYSE:DGX),(NASDAQ:NEO) EQNX::TICKER_END
Via
FinancialNewsMedia
Is There A Blood Test for Alzheimer's? Progress Underway, But Not Quite Ready
October 11, 2023
Blood tests for diagnosing Alzheimer's disease are eagerly awaited, but it may be a couple of years before they become a routine diagnostic tool. While several blood tests for Alzheimer's diagnosis are...
Via
Benzinga
Quest Diagnostics: Dividend Insights
July 05, 2023
Via
Benzinga
Analyst Ratings for Quest Diagnostics
June 29, 2023
Via
Benzinga
Biden Administration Restarts Distribution Of Free At Home COVID-19 Tests, After Suspending For Year
September 21, 2023
In response to the escalating spread of the virus nationwide, the Biden administration declared that it would recommence offering free at-home COVID tests to American households starting next Monday.
Via
Benzinga
Exposures
COVID-19
3 Pharma Stocks to Buy as Summer COVID Cases Spike
August 23, 2023
Covid cases are on the rise, which might be the booster shot these top pharma stocks for Covid need to regain their trajectory.
Via
InvestorPlace
Exposures
COVID-19
Why Bionano Genomics Stock Tanked Today
August 14, 2023
A CFO departure shines a light on some of the company's recent struggles.
Via
The Motley Fool
More Alzheimer's Treatments Are Coming: This Company Can Help With Early Detection
August 09, 2023
Alzheimer's is a huge problem, and earlier detection could make a big difference.
Via
The Motley Fool
Looking for a Bargain? 3 Stocks to Buy That Are Down 10% in 2023
August 02, 2023
Investors looking for bargain stock opportunities in a rapidly-rising market should consider these companies that haven't yet bounced back.
Via
InvestorPlace
Quest Diagnostics Stock Falls on Lower Q2 Revenue and Profits from Lower Productivity Effects, Tightened Outlook
July 26, 2023
Quest Diagnostics Inc (NYSE: DGX) posted Q2 FY23 adjusted EPS of $2.30, down 2.5% Y/Y, beating the consensus of $2.27.
Via
Benzinga
Sustaining Growth Momentum: Quest Diagnostics Continues to Excel and Reports Rising Profits
July 25, 2023
At the end of July 25, 2023, Quest Diagnostics (NYSE:DGX) will reward its shareholders with a dividend payout of $0.71 per share, demonstrating an annualized dividend yield of 2.15%. Remember, only...
Via
Benzinga
Quest Diagnostics, Keysight Technologies And A Stock Up 42% Year To Date On CNBC's 'Final Trades'
July 19, 2023
On CNBC’s "Halftime Report Final Trades," Jason Snipe of Odyssey Capital Advisors said he likes Quest Diagnostics Incorporated (NYSE: DGX) here.
Via
Benzinga
Biden Administration Releases Revised Guidance For Medicare Drug Price Negotiation Amid Industry Lawsuits
June 30, 2023
The Centers for Medicare and Medicaid Services released revised guidance on using its authority with pharmaceutical manufacturers
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 29, 2023
June 29, 2023
Via
Benzinga
FDA Readies Proposal for Increased Oversight on Lab-developed Tests
June 08, 2023
The FDA is preparing to increase regulation of a widely used class of tests conducted by laboratories to detect cancer, measure cholesterol, and identify other health issues. The FDA is developing a...
Via
Benzinga
Want Growing Passive Income? Consider Buying This Stock
May 24, 2023
This maker of diagnostics tests has delivered 13 years of dividend growth to shareholders.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.